To identify critical amino acids within the central conserved region of recombinant human cAMP-specific phosphodiesterase 4 subtype A (rhPDE4A), we engineered the expression of point mutants in a fully active rhPDE4A/Met201-886. When histidine residues at positions 433, 437, 473, and 477, which are highly conserved among all PDE families, were changed independently to serine residues, cAMP hydrolyzing activities were substantially reduced or abolished. The ability of these mutants to bind prototypical PDE4 inhibitors 
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The PDE4A subtype is the largest protein among the PDE4s, consisting of 886 amino acids with a native molecular mass of 110 kDa (5) . A notable feature of PDEs is their ability to bind the archetypical PDE4-selective inhibitor (R)-rolipram with both a high affinity (K d ϭ 1 nM) and a low affinity (K d ϭ 50 -100 nM) (19) (20) (21) . This unique characteristic is thought to reflect the ability of hPDE4A to exist in two distinct and enzymatically active conformational states: one with a catalytic site that binds rolipram with a high affinity (termed HPDE4) and a second with a catalytic site that binds rolipram with a low affinity (termed LPDE4) (19) .
A more recently synthesized compound, RP 73401, selectively inhibits PDE4 with very high potency (IC 50 ϳ 0.5 nM) (17, 19) . This compound does not distinguish between HPDE4 and LPDE4 but instead binds with equal affinity (K d ϭ 0.4 nM) to both forms of the enzyme (19) . Additional studies suggest that cAMP, rolipram, and RP 73401 all bind to a central conserved region of hPDE4A, spanning amino acids 332-722 (19) .
The critical amino acids within the catalytic core of hPDE4A that are responsible for substrate binding and catalysis have not been identified. However, Jin et al. (8) demonstrated that the substitution of Thr349 with either alanine or proline in rat PDE4D (corresponding to Thr544 in hPDE4A) abolished catalytic activity. In contrast, the replacement of Thr349 with a serine, a more conservative change, yields an enzyme that retains a degree of catalytic activity. This implies an important role for Thr349 as a H-bond donor in PDE4. Other studies on the rolipram sensitivity of spontaneous single-site mutations of rat rPDE4B have yielded interesting information on inhibitor binding (22) . Three catalytically active mutants were identified as being rolipram resistant: D239N (position 440 in hPDE4A), T405A (position 606), and Val449A (position 650). In addition to being insensitive to rolipram, the T405A mutant is insensitive to IBMX.
In an attempt to improve our understanding of the molecular basis for substrate binding, substrate turnover, and inhibitor binding in PDE4, we evaluated the functional consequences of changing single amino acids within the central conserved region of hrPDE4A. The objectives were to (i) identify specific amino acids that are critical for catalytic activity and (ii) determine whether the amino acids that are important for substrate binding or turnover are also important for inhibitor binding. 4 and 5.15 ϫ 10 4 dpm/pmol, respectively. Expression plasmid construction. The PDE-deficient Saccharomyces cerevisiae strain GL62 is isogenic to GL61 (MAT␣ leu2 ura3-52 ade1 his3 trp1 lys2-208 pde1::LEU2 pde2::URA3 pep4::HIS3) and has been previously described (9, 23) . A yeast expression plasmid expressing rhPDE4A was previously described as p138NB/Met201-886 (19) . It lacks ϳ600 base pairs of 5Ј open reading frame sequence and predicts a truncated protein lacking ϳ200 amino acids at the NH 2 terminus (4, 5). The recombinant protein, which we designate Met201-886, was engineered to contain nine non-native amino acids (MCPF-PVTTV) at the NH 2 terminus fused to Pro210. Thus, this construct encodes a fusion protein consisting of a nonapeptide coupled to Pro210 on hPDE4A. Our original hPDE4A-encoding cDNA was designated hPDE-1 and engineered for expression using polymerase chain reaction (4, 23, 24) . The amino acid sequence of this protein is identical to that of h6.1 as described by Sullivan et al. (25) . This truncated rhPDE4A protein has kinetic characteristics that are identical to those of the native enzyme (21, 25) .
Experimental Procedures

Inhibitors. Unlabeled and tritiated rolipram (4-
Site-directed mutagenesis. A 2.4-kb SalI/XbaI fragment of hPDE-1 sequence (4) encoding Met201-886 was subcloned into the mutagenesis vector phagemid pALTER-1 (Promega, Madison, WI). The oligonucleotides used for mutating amino acids were 5Ј-TGCGTGCAGGCTGTTGGAGTAGGCCA-3Ј for H433S, 5Ј-GTCA-GCTGCGGACAGGCTGTTATGGTAG-3Ј for H437S, 5Ј-GGGTGATC-CACATCGGAGATGGCAGCCGCG-3Ј for H473S, 5Ј-ACCCCA-GGGGAATCCACATCGTGGATG-3Ј for H477S, 5Ј-CTCATCGTTGA-ACATGAGCGCC-3Ј for Y496T, 5Ј-CTCATCGTTGAACATGAGCG-CC-3Ј for Y496F, 5Ј-GGCCAGGTGGTTATTCTCGAG-3Ј for H505N,  5Ј-CACGGCCAGGTTGTGATTCTC-3ЈforH506N,5Ј-GAAGATGTCGG-AGTTGTACTC-3Ј for C519S, and 5Ј-CATGAGCGCCAGCTCCGA-GCTGCTGTTGATGAGGAACTGG-3Ј for the double mutant T489S/ N490S. Oligonucleotides were synthesized by Dr. Ganesh Sathe (Department of Gene Expression Sciences, SmithKline Beecham Pharmaceuticals). Propagation of single-stranded DNA and mutagenesis reactions were performed according to the supplier's directions (Promega). Briefly, 1.25 pmol of phosphorylated mutant oligonucleotide and 0.25 pmol of ampicillin repair oligonucleotide were annealed to 0.05 pmol of single-stranded template DNA. The annealing reaction mixture was maintained at 70°for 10 min and allowed to cool slowly to room temperature for 30 min before it was placed on ice. Second-strand synthesis was at 37°for 90 min in the presence of all four nucleotides, 10 units of T4 DNA polymerase, and 2 units of T4 DNA ligase.
The entire synthesis reaction mix was transformed into Escherichia coli BMH 71-18 mut S, and cells were grown for 24 hr at 37°i n the presence of 125 g of ampicillin/ml in liquid LB. Plasmid DNA from these cultures was prepared by alkaline lysis (26) , and 0.1 g of plasmid DNA was transformed into E. coli JM 109. Single colonies of the resulting transformants were picked, and plasmid DNA was prepared. To confirm that the desired base changes had occurred, several clones were sequenced by dideoxy sequencing with Sequenase 2.0 (United States Biochemical, Cleveland, OH) according to the manufacturer's instructions.
Expression of single-site mutants. The yeast expression plasmid p138NB contains the TRP1-selectable marker and a partial 2-micron sequence for maintenance at high copy number. Expression is driven by the copper-inducible CUP1 promoter with a polylinker site just downstream, followed by the yeast CYC1 transcriptional terminator (23) . Expression plasmids containing various single-site mutants of rhPDE4A/Met201-886 ( Fig. 1) were transformed into S. cerevisiae strain GL62 according to the lithium acetate method (27) . Expression of PDE4 was induced by 150 M CuSO 4 and allowed to proceed for 6 hr. Cells were harvested, washed, resuspended, and lysed as previously described (23) . Strain GL62 contains deletions of both genes encoding the yeast cAMP PDEs and therefore is devoid of endogenous enzymatic activity. It also contains a deletion of the PEP4 gene, which encodes an aspartyl protease; stable rhPDE4A expression in yeast is dependent on the absence of this protease (23) .
Quantification of protein expression. Expression of mutant and wild-type proteins was monitored by immunoblotting as previously described (19, 23) . Some of the mutant proteins described in this study expressed to lesser amounts compared with the nonmutated hrPDE4A/Met201-886 (Fig. 2) . In studies in which Scatchard analyses for determining B max and kinetic analyses were described, protein expression of the various mutants was quantified in more detail by immunoblotting with an antibody raised against a GalKhPDE4A fusion protein (23) and 125 l-labeled protein A (specific activity, Ͼ30 Ci/g, ICN Biomedicals, Irvine, CA). Different amounts of protein lysates (100 ng to 10 g) were analyzed in a single gel for each of the mutated proteins to ensure a linear range of detection. Blots were exposed to the phosphor screen of a PhosphorImager (Molecular Dynamics, Sunnyvale, CA) for 2 hr and analyzed using the software ImageQuant. To compare and normalize different expression levels, various amounts of lysates containing hPDE4A/ Reactions were run at 30°initiated by the addition of 50 l of yeast supernatant of several different dilutions, depending on the activity of the mutant proteins, to 100 l final volume and terminated after 30 min by placing the reaction mixtures in a heating block at 100°for 1 min. Separation and estimation of cyclic nucleotides and 5Ј-nucleotides were conducted as previously described (28) . For kinetic measurements, [ 3 H]cAMP was kept constant at 0.035 M and supplemented with nonlabeled cAMP to give final concentrations of 0.045-100 M. Reaction times were varied between 1 and 60 min, so that Յ20% of the substrate was hydrolyzed during the assay. For inhibitor studies, the enzyme was preincubated at 30°for 10 min before the start of the reaction through the addition of the appropriate mixture of substrate and inhibitor.
For the determination of K i values, assays were conducted using 0.5, 1, 2, and 5 M cAMP for Met201-886; 2, 5, 10, and 20 M cAMP for H505N; and 10, 20, 40, and 60 M cAMP for H506N. Specific activities were calculated by first determining the different expression levels of the constructs as described above.
Inhibitor binding assay. Binding assays were performed at 30°f or 1 hr in 0.5 ml of PDE buffer (50 mM Tris⅐HCl, pH 7.5, 5 mM MgCl 2 ) containing 0.05% bovine serum albumin as previously described (20, 21) . Reactions were started by the addition of 20-50 l of PDE4A to the reaction mixtures.
For saturation binding experiments, the concentration of Assay volumes were increased to 5 ml, and equilibration was carried out at 4°for 30 min. These modifications to the assay were made to limit hydrolysis of the competitor cAMP during the incubation period. Preliminary experiments were conducted to validate these modifications. Under standard experimental conditions for the radioligand binding assay, 83 Ϯ 12% and 41 Ϯ 6% of total cAMP was hydrolyzed at substrate concentrations of 3 and 30 M, respectively. In contrast, substrate degradation was negligible under the modified assay conditions, so that Ͻ2% of the total cAMP content was lost using either substrate concentration.
Binding reactions were stopped by placement of the mixtures on ice before subjecting them to rapid filtration (Brandel Cell Harvester, Montreal, Quebec, Canada) through Whatman (Clifton, NJ) GF/B filters that had been equilibrated with 0.3% polyethylenimine. The filters were washed three times with 2.5 ml of ice-cold PDE buffer each time, dried, and counted via liquid scintillation counting. Nonspecific binding was 1-10% of the specific binding. This assay has been previously described in greater detail (20, 21) . Under these conditions, [ 3 H]RP 73401 detects both conformational states of PDE4A (i.e., LPDE4 plus HPDE4), whereas [ 3 H]-(R)-rolipram binds only to HPDE4 (18) . Analyses of saturation and competition binding experiments were carried out using the Acufit computer program (Beckman Instruments, Columbia, MD).
Results and Discussion
In the current study, single amino acids within the conserved region of rhPDE4A were changed to examine the involvement of functional groups in substrate catalysis and inhibitor binding. Fig. 1 shows the amino acid sequence of rhPDE4A between positions 415 and 520 within the central conserved region and the residue changes therein. These (5) . Highlighted, amino acids that were changed in the current study. Numbers, positions within rhPDE4A; arrows, newly introduced amino acids; UCR I and II, upstream conserved regions I and II (5); hatched regions, catalytic domain contained within residues 332-722 (19).
Fig. 2.
Immunoblot analysis of the expression of single-site mutants of rhPDE4A in S. cerevisiae. Supernatant fractions of lysates of strain GL62 containing single-site mutants of rhPDE4A were prepared as described in the text. Proteins were separated, transferred, probed, and analyzed as previously described (19, 23) . changes were performed using the NH 2 -terminally truncated form rhPDE4A/Met201-886. This protein retains the previously described high affinity rolipram-binding activity and possesses the same kinetic properties as the full-length protein Met1-886 (19, 21) .
Rationale for mutating histidine residues. A major focus of our effort was on the role of histidine residues in the catalytic domain. The rationale for targeting histidine residues was based on previous observations suggesting an important role of this amino acid in the function of PDEs. First, hydrolysis of cAMP by PDEs is thought to occur by nucleophilic substitution reactions that involve base/acid-catalyzed hydrolysis of the phosphoester bond (30) . Second, studies using substrate analogues suggest that cAMP binds to the enzyme via hydrogen bonding between the protein and N6 and N7 of the adenine ring (31, 32) . Thus, because histidine can function as a H-bond donor as well as a H-bond acceptor at physiological pH, this amino acid may be involved in both substrate binding and hydrolysis. Finally, divalent cations such as Mg 2ϩ are required for cAMP hydrolysis and (R)-rolipram binding (20, 21) . 1 These divalent cations bind directly to the enzyme, 1 and histidine, along with serine, may be required for metal binding. Alteration of these residues could thus yield an inactive enzyme. Consistent with a critical role for histidine, the histidine-modifying reagent diazopyrocarbonate abolishes catalytic activity of rhPDE4A (33) .
Because of the potential importance of histidine residues in the expression of PDE catalytic activity, our initial targets for mutagenesis were His427, His433, His437, His446, His473, His477, His505, and His506. These are conserved among all mammalian PDEs, perhaps reflecting a critical structural or functional role.
Modification of His427 and His446. His427 and His446 of rhPDE4A are not present in the Drosophila dunce gene product (34) . Instead, valine and asparagine are present at these positions. The Drosophila dunce gene product is a member of the PDE4 family that is insensitive to inhibition by Ro 20-1724 and other archetypical PDE4 inhibitors (35) . We reasoned that the lack of a histidine residue at either position could be responsible for insensitivity to PDE4 inhibitors. However, contrary to our expectations, H427V and H446N in rhPDE4A were still catalytically active and bound (R)-rolipram with high affinity (Table 1) . Moreover, these mutants were sensitive to inhibition of catalytic activity by (R)-rolipram (not shown). Therefore, His427 and His446 are not required for the activity of the prototypical PDE4 inhibitor rolipram in rhPDE4A.
Modification of His433, His437, His473, and His477. Catalytic activity was abolished when His433 or His437 was changed to serine and was reduced by 60-98% when His473 or His477 was changed to serine or arginine (Table 1) . Similarly, (R)-rolipram binding was either not detectable or reduced by Ͼ90% in the corresponding mutants (Table 1) . These changes were considered to be fairly conservative because serine and arginine as well as glutamine (see Table 1 ) can function as H-bond donors at physiological pH. The results indicate that these histidine residues are required for catalytic activity and (R)-rolipram binding under standard assay conditions. One possibility is that they are involved directly with inhibitor and substrate binding. His473 and His477 are the integral histidine residues in the PDE consensus sequence HDX 2 HX 4 N (36). Alternatively, His433 and Table 2 . PDE5 seems to be a zinc hydrolase, and these histidine tandems are critical for chelation of this metal (37) . The presence of these histidine tandems, along with their requirement for catalytic activity, are consistent with the suggestion that PDE4s are also zinc hydrolases. Finally, of course, we cannot eliminate the possibility that these histidines are important in maintaining the structural integrity of the enzyme.
Differential effects of H505N and H506N.
Changing either His505 or His506 to asparagine reduced the cAMPhydrolyzing activities of the mutants by 80-90% (Table 1) . These results are consistent with those of Jin et al., who reported a complete loss of catalytic activity when His311 in rat PDE4D (which corresponds to His506 in hPDE4A) was changed to asparagine, aspartic acid, or tyrosine (8) . However, despite the substantial decrease in catalytic activities of the His505 and His506 mutants, [ (Table 1) . This is in contrast to the loss of both catalytic and binding activity observed in the His433, His437, His473, and His477 mutants.
Superficially, the results with the His505 and His506 mutants suggested that these residues are important for the binding or catalysis of substrate but not the inhibitor. This prompted a more detailed examination of cAMP hydrolysis and inhibitor binding. Michaelis-Menten analysis of cAMP hydrolysis revealed a 3-fold increase in the K m value and a 65% reduction in the V max value for H505N and a 11-fold increase in the K m value and a 72% reduction in the V max value for H506N (Fig. 3, Table 2 ). The catalytic activities for the mutant enzymes remained sensitive to (R)-rolipram and RP 73401, with IC 50 values similar to those of hPDE4A/ Met201-886 (Table 2 ). These results indicate that alteration of His505 and His506 reduces both the affinity and turnover of cAMP but has little effect on inhibitor binding, suggesting a difference in the mode of substrate binding versus inhibitor binding.
The effect of altering His505 and His506 on the potency of several inhibitors was explored in greater depth by examin- Table 3 (36) , versus the inhibitor concentrations were replotted and fit to a straight line using KaleidaGraph. The point of intersection of each line with the horizontal axis gives ϪK i values, assuming that each inhibitor is competitive with substrate. K i values are summarized in Table  3 . Values are mean Ϯ standard error of three experiments. F, Met201-886. f, H505N. å, H506N. For kinetic measurements, substrate concentration was varied from 0.045 to 100 M cAMP. Values for V max and K m were determined as described in the text using the computer program KaleidaGraph. For inhibitor studies, cell lysates were incubated at room temperature for 10 min with various concentrations of inhibitor: 0.03-300 M (R)-rolipram and 0.03-300 nM RP 73401. The reaction was initiated by the addition of 1 M cAMP. V max values were normalized for different expression levels using rhPDE4A/Met201-886 as a standard, as described in Experimental Procedures. Data indicate the mean Ϯ standard error of three separate experiments.
Met201-886 H505N H506N
V max (nmol/min/ml) 23 Ϯ 3 7.9 Ϯ 2.3 ing enzyme activity in the presence of a broad range of cAMP and inhibitor concentrations (Fig. 4, Table 3 ). In addition to RP 73401 and rolipram, the PDE4-selective inhibitor BRL 61063 and the nonselective inhibitor IBMX were examined. The latter two compounds have structural similarities to cyclic nucleotides and, like RP 73401 and rolipram, are believed to bind to the catalytic site of PDEs. Interestingly, the K i values for IBMX varied in a fashion similar to those of cAMP; the K i value increased 2-fold for H505N and 5-fold for H506N (Table 3 ). In contrast, the K i values for BRL 61063, RP 73401, and (R)-rolipram were unaltered in these histidine mutants (Table 3 ). These data suggest that cAMP and the nonselective inhibitor IBMX bind to hPDE4A in a manner distinct from that of the PDE4-selective inhibitors.
To evaluate the effect of mutation of His505 and His506 on inhibitor and substrate binding, radioligand binding studies were conducted. Mutation of hPDE4A/Met201-886 to H505N or H506N had virtually no effect on the binding affinities of [ 3 H]-(R)-rolipram, which reflects the fact that the former ligand binds with the same high affinity to two unique structural conformers of hPDE4A, whereas rolipram binds with high affinity to only one form (19) . The B max value for the radioligands was essentially unchanged in H505N but was reduced by 60-70% in H506N. The decreased B max value of H506N suggests that the reduced cAMP V max value of this mutant reflects a decrease in the proportion of expressed enzyme molecules that are catalytically active rather than a true change in substrate turnover (i.e., k cat ).
Rolipram and RP 73401 compete with cAMP for binding at the catalytic site (19) . 1 Consequently, we evaluated the ability of cAMP to compete for 2 nM Fig. 5 ). Likewise, the 11-fold increase in the cAMP K m value for H506N was mirrored by a 13-fold increase in the IC 50 value for cAMP in this mutant. Interestingly, sequence comparison of hPDE3A, hPDE4A, and hPDE7A reveals the presence of a conserved peptide SerValLeuGluAsnHisHis, in which the two histidines are analogous to His505 and His506 in PDE4A (results not shown). This peptide also seems to be conserved among all other PDEs sequenced thus far, again suggesting an important involvement of this motif in the structure or function of PDEs.
Mutational analysis of conserved, nonhistidine amino acids. Other functional amino acids that might be involved with substrate binding and catalysis include those containing a hydroxyl group such as serine, threonine, or tyrosine. These residues could serve as electron donors for nucleophilic attack. In addition, a seven-amino acid stretch, GluLeuAlaLeuMetTyrAsn (position 491-497 in hrPDE4A), is conserved among most but not all PDEs and is also contained Table 4 . (Table 1) . This implies that a hydroxyl group at this position is required for optimal catalytic activity and inhibitor binding.
The Drosophila dunce gene product also contains the above-mentioned seven-amino acid stretch. Directly preceding this peptide, however, is a sequence of three consecutive serine residues that differs from the sequence found in human PDE4A (see Fig. 1 ). To study the potential influence of this serine stretch toward rolipram sensitivity, we changed T489S and N490S simultaneously in hrPDE4A. No changes in catalytic activity or (R)-rolipram binding were noted in this mutant (Table 1) .
Finally, replacement of Cys519 with serine reduced catalytic activity by ϳ60% but had no effect on [ 3 H]-(R)-rolipram binding (Table 1) . Although the biochemical characteristics of C519S were not examined in detail, this result hints that, similar to His506, Cys519 may influence catalytic activity but not inhibitor binding.
Conclusions. Taken collectively, these data suggest that His506 of hPDE4A is a key residue involved in the binding of cAMP-but not PDE4-selective inhibitors. On the other hand, His505 has a lesser role in cAMP binding but seems to influence substrate turnover. None of the nondestructive amino acid changes made in this study had an impact on the binding of PDE4-selective inhibitors. Previous studies by Pillai et al. (22) , however, demonstrated that alteration of Asp239 in rat PDE4B (position 440 in hPDE4A) to an asparagine decreased the inhibitory potency of rolipram by 400-fold. Interestingly, the same change had virtually no effect on the inhibitory potency of IBMX (22) . Conversely, results from the current study indicate that changing His506 to asparagine increased the K i value of IBMX by 5-fold but had no effect on the affinity of rolipram, RP 73401, or BRL 61063. An implication of these results is that substrate analogues such as IBMX bind to PDE4A in a manner that is different from structurally diverse PDE4-selective inhibitors. Although further mutational analyses may yield useful information, clear insights into the roles of specific amino acids in cAMP hydrolysis and inhibitor binding await more definitive structural approaches.
